Supernus Pharmaceuticals Inc
NASDAQ:SUPN

Watchlist Manager
Supernus Pharmaceuticals Inc Logo
Supernus Pharmaceuticals Inc
NASDAQ:SUPN
Watchlist
Price: 36.22 USD 1.12% Market Closed
Market Cap: 2B USD
Have any thoughts about
Supernus Pharmaceuticals Inc?
Write Note

Supernus Pharmaceuticals Inc
Pre-Tax Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Supernus Pharmaceuticals Inc
Pre-Tax Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Pre-Tax Income CAGR 3Y CAGR 5Y CAGR 10Y
Supernus Pharmaceuticals Inc
NASDAQ:SUPN
Pre-Tax Income
$72.5m
CAGR 3-Years
-13%
CAGR 5-Years
-13%
CAGR 10-Years
N/A
Johnson & Johnson
NYSE:JNJ
Pre-Tax Income
$17.6B
CAGR 3-Years
-3%
CAGR 5-Years
2%
CAGR 10-Years
-2%
Bristol-Myers Squibb Co
NYSE:BMY
Pre-Tax Income
-$6.9B
CAGR 3-Years
-18%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Pfizer Inc
NYSE:PFE
Pre-Tax Income
$3.9B
CAGR 3-Years
-43%
CAGR 5-Years
-3%
CAGR 10-Years
-12%
Merck & Co Inc
NYSE:MRK
Pre-Tax Income
$13.7B
CAGR 3-Years
23%
CAGR 5-Years
4%
CAGR 10-Years
7%
Eli Lilly and Co
NYSE:LLY
Pre-Tax Income
$10.2B
CAGR 3-Years
14%
CAGR 5-Years
17%
CAGR 10-Years
12%
No Stocks Found

Supernus Pharmaceuticals Inc
Glance View

Market Cap
2B USD
Industry
Pharmaceuticals

Supernus Pharmaceuticals, Inc. engages in the development and commercialization of products for the treatment of central nervous system diseases. The company is headquartered in Rockville, Maryland and currently employs 575 full-time employees. The company went IPO on 2010-12-28. The firm is focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. Its diverse neuroscience portfolio includes treatments for epilepsy, migraine, hypomobility in Parkinson’s Disease (PD), cervical dystonia, and chronic sialorrhea. Its commercial portfolio of products includes Trokendi XR (topiramate) and Oxtellar XR (oxcarbazepine) for the treatment of epilepsy. Its APOKYN (apomorphine hydrochloride injection) is a product indicated for the acute, intermittent treatment of hypomobility in patients with advanced parkinson’s disease (PD). Its XADAGO (safinamide) is a product indicated as adjunctive treatment to levodopa/carbidopa in patients with PD. Its MYOBLOC (rimabotulinumtoxinB) is a product indicated for the treatment of cervical dystonia and sialorrhea in adults. Its pipeline of CNS product candidates includes SPN-812, SPN-817, SPN-820, SPN-830 and MYOBLOC.

SUPN Intrinsic Value
38.06 USD
Undervaluation 5%
Intrinsic Value
Price

See Also

What is Supernus Pharmaceuticals Inc's Pre-Tax Income?
Pre-Tax Income
72.5m USD

Based on the financial report for Sep 30, 2024, Supernus Pharmaceuticals Inc's Pre-Tax Income amounts to 72.5m USD.

What is Supernus Pharmaceuticals Inc's Pre-Tax Income growth rate?
Pre-Tax Income CAGR 5Y
-13%

Over the last year, the Pre-Tax Income growth was 96%. The average annual Pre-Tax Income growth rates for Supernus Pharmaceuticals Inc have been -13% over the past three years , -13% over the past five years .

Back to Top